MBIO News and Press, Mustang Bio Inc. From 12/07/20

Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...

Mustang Bio (MBIO) is on watch after Oppenheimer tips on an "excellent clinical profile" for MB-106 at the ASH conference."The poster presentation included results for nine efficacy-evaluable NHL patients—including five who were not in the published ASH abstract. MB-106 delivered impre...

Data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity 89% overall response rate and 44 % complete response rate in patients treated with modifi...

Gainers: [[OBLN]] +81%. [[MRIN]] +9.8%. [[FATE]] +8.8%. [[CRNX]] +6.7%. [[PROG]] +6.1%.Losers: [[HX]] -6.2%. [[INN]] -6.2%. [[RIDE]] -5.6%. [[MBIO]] -4.4%. [[EVK]] -3.8%. For further details see: RIDE, FATE, MBIO and MRIN among after-hours movers

4 Biotech Penny Stocks To Watch Right Now Biotech stocks and penny stocks go hand-in-hand in many ways. One of the clearest is how speculation tends to drive momentum. Much like penny stocks, traders speculate on what potential outcomes may be during different phase trials that comp...

WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

5 Biotech Stocks To Watch This Week When it comes to biotech stocks , there’s plenty to take into account. This goes for biotech penny stocks as well. Considering that many of these companies are in the preclinical or clinical stages, there’s a higher chance that t...

WORCESTER, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

WORCESTER, Mass. and MUNICH, Germany, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hema...

Fortress Bio controls a network of companies that are engaged in drug development activities. The company identifies early stage assets, and helps to develop them, guide them through the clinical trial process, and manage commercialisation activities. Most of its deals are structu...